MedTrace Logo

Combined Anabolic Therapy

NCT06558188 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-17

No results posted yet for this study

Summary

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Conditions

Interventions

DRUG

Romosozumab

romosozumab 210 milligrams monthly

DRUG

Teriparatide

teriparatide 20 micrograms daily

Sponsors & Collaborators

Principal Investigators

  • Benjamin Leder, MD · MGH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-03
Primary Completion
2027-12-30
Completion
2028-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06558188 on ClinicalTrials.gov